Loading...
OTCM
CALZF
Market cap438mUSD
Oct 14, Last price  
0.63
Name

Polynovo Ltd

Chart & performance

D1W1MN
OTCM:CALZF chart
P/E
—
P/S
—
EPS
0.01
Vol. 1Y
—
Shs. 5Y
1.10%
Rev. 5Y
37.58%
Div Yld LY
—
Div Yld TTM
—
Revenues
144m
+12.94%
4,36600121,910388,201241,635112,56560,19622,3393,277,0003,620,0006,554,00014,044,00022,156,00029,158,00041,440,00065,241,000103,192,000127,243,000143,706,000
Net income
7m
-44.45%
-13,407,000-4,441,000-1,830,000-1,862,000-2,917,000-2,699,000-1,492,000-2,936,000-1,302,000-3,062,000-5,006,000-5,974,000-3,190,000-4,194,000-4,605,000-1,193,000-4,925,0005,261,00013,214,0007,341,000
CFO
23m
+638.44%
-13,424,569-4,112,194-3,417,139-2,830,852-2,930,088-2,665,884-2,325,918-2,612,850-2,567,281-3,556,419-5,161,533-6,877,961-3,369,733-402,564-248,737-2,056,633-5,933,0673,683,0003,148,00023,246,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Key people

Non-Executive Independent Chairman of the Board · since 2014
Bruce Peatey
Chief Executive Officer · since 2025
Jan-Marcel Gielen
Chief Financial Officer · since 2026
Ed Graubart
President - North America · since 2024
David Morris
President - Asia Pacific · since 2024
Ingrid Anderson
Chief People Officer · since 2024
David Mcquillan
Chief Technical and Scientific Officer · since 2022
Aurore Mulkens
Vice President - Quality Affairs · since 2023
Amy Demediuk
General Counsel, Company Secretary · since 2026
Robyn Elliott
Managing Director, Executive Director · since 2025
Joseph Amaral
Chief Medical Officer · since 2024
Ahmed Hassan
Director of Operations · since 2022
Non-Executive Director · since 2025
Non-Executive Independent Chairman of the Board · since 2025
Christine Emmanuel-Donnelly
Non-Executive Independent Director · since 2024
Non-Executive Independent Director · since 2024
IPO date
Nov 26, 1998
Employees
218
Domiciled in
AU
Incorporated in
AU
Headquarters & legal address
Unit 2, 320 Lorimer Street
Port Melbourne, VIC 3207
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT